Extracellular matrix

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Retrieved on: 
Thursday, April 18, 2024
USD, Mayo Clinic, CELU, Management, CTM, DSM-IV codes, Conference, Development, Engineering, Clinical professor, UCM, Patient, Extracellular matrix, Healing, Regenerative medicine, Regeneration, Therapy

The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”

Key Points: 
  • The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”
    Celularity’s abstract explores the application of various decellularized placental biomaterials, including connective tissue matrix (CTM) and umbilical cord matrix (UCM), in tendon management, both in vitro and in vivo.
  • The abstract focuses on assessing the biomaterials’ biomechanical properties, immunomodulatory effects, and preclinical outcomes in clinically relevant models to advance their potential in tendon repair.
  • I am very excited about the growing opportunity and potential of our decellularized placental biomaterials in tendon management and healing.
  • These data indicate that human placental decellularized biomaterials may represent a promising matrix suitable for tendon management and healing.

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Retrieved on: 
Monday, April 15, 2024
Pelvis, Burns, Umbilical cord, Tissue, CELU, Extremities, Form, Environment, Extracellular matrix, Good manufacturing practice, Regenerative medicine, Growth, Medical imaging

FLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”) a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Key Points: 
  • Celularity’s predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next-generation products in this technology.
  • Under the plan implemented, senior executives are foregoing a portion of their 2024 cash salary as well as payment in cash of any performance bonus payable in 2024.
  • Celularity’s advanced biomaterial product pipeline consists of four commercial-stage products and three investigational products.
  • Interfyl®, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate integumental tissue.

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on: 
Wednesday, March 13, 2024
Scientific Reports, Health, Skin care, ECM, Face, Retinol, Radical (chemistry), Cell nucleus, Peptide, Extracellular matrix, DNA, Research, ROS, Mitochondrion, Methylene blue, Skin, Collagen, DNA repair, UMD, Identity matrix, Human, Ageing, Neck, Cosmetics

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points: 
  • Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
  • Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
  • Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
  • To view an enhanced version of this graphic, please visit:
    The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Retrieved on: 
Tuesday, April 9, 2024
TME, Lipid, Extracellular matrix, Gene, Enzyme, Survival, Patient, SAN, Tumor microenvironment, RNA, Cancer, Pembrolizumab, Protein, AACR, NCNA, Lipid metabolism, Dicarboxylic acid, Messenger, PD-1, Vaccine

SAN DIEGO, April 09, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The tumor microenvironment (TME) is a complex interplay of various cell types, extracellular matrix, signalling molecules and physical factors that collectively influence tumor growth.
  • Lipids play an important role in the TME, contributing to various aspects of cancer progression and therapy resistance.
  • They also further explain the compelling clinical data we have generated with NUC-7738 as a monotherapy and in combination with pembrolizumab.
  • Our translational data help us to understand these clinical observations and guide the optimal development pathway for NUC-7738.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Research, Extracellular matrix, B cell, ECM, Regeneration, Idiopathic pulmonary fibrosis, AT2, Inflammation, Lung, SWAP, Respiratory Research, Macrophage, IPF, Pulmonary fibrosis, Fibrosis, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-0.... The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.

Key Points: 
  • The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.
  • Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology.
  • In pulmonary fibrosis, multiple cell types may need to be targeted to provide a regenerative environment facilitating repair.
  • “This work published in Respiratory Research represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 25, 2024
Tax, Growth, Tufts University, Patient, Extracellular matrix, Classification, Sale, Acquisition, Nature, Adjustment, SMTI, Infection, Depreciation, GAAP, Peptide

Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.

Key Points: 
  • Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.
  • The Company’s products were contracted or approved to be sold in more than 3,000 hospitals/ambulatory surgery centers as of December 31, 2023.
  • In October 2023, Sanara recorded its first sale of ALLOCYTE® Plus, a human cell and tissue-based product.
  • In November 2023, Sanara announced the publication of a retrospective study involving 5,335 patients.

West Point Optical Group, LLC and Verséa Ophthalmics, Inc. Announce Partnership Supply Agreement for  BIOVANCE®and BIOVANCE® 3L Ocular

Retrieved on: 
Wednesday, April 3, 2024
Health, Optical, Surgery, WPOG, Extracellular matrix, Allotransplantation, Partnership, Patient, Wound healing, Pearle Vision, OD, Ophthalmic, Telescopic sight

BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.

Key Points: 
  • BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
  • BIOVANCE® 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease.
  • As a barrier membrane, BIOVANCE® 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
  • “We are excited to partner with Verséa Ophthalmics allowing our eye care professionals to deliver the benefits of BIOVANCE® and BIOVANCE® 3L Ocular products to their patients,” said John Womack, OD, West Point Optical Group’s Chief Medical Officer.

BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell

Retrieved on: 
Thursday, March 7, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Science, Oncology, Other Science, Infection, Architecture, Bangladesh Technical Education Board, Follicular lymphoma, MD, Escape Room, Extracellular matrix, Manuscript, Apoptosis, National Cancer Institute, Lymph, Myelocyte, Malignancy, Death, ZIA, Tumor microenvironment, Medicine, Patient, Survival, Lymphoma, B cell, Vaccine

Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.

Key Points: 
  • Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.
  • Despite the urgent need, current clinical tools inadequately predict disease behavior, underscoring the necessity for risk stratification methods, particularly for early relapsers.
  • The study, led by researchers at the National Institute of Allergy and Infectious Diseases and National Cancer Institute in collaboration with BostonGene, employed a multi-modal approach to comprehensively examine cell-intrinsic and -extrinsic factors governing disease progression and therapeutic outcomes in FL patients enrolled in a prospective clinical trial.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 7, 2024
Extracellular matrix, Tech, Cell, Eli Lilly, AI, Phenotype, Biomarker, Patient, Fibroblast, Idiopathic pulmonary fibrosis, Drug discovery, Messenger, Myofibroblast, AbbVie, Disease, IPF, ADMET, Pharmaceutical industry

BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.

Key Points: 
  • BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.
  • This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
  • Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.
  • By inhibiting myofibroblasts' deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases.

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Retrieved on: 
Thursday, February 1, 2024
Traction, Growth, Umbilical cord, Extracellular matrix, Extremities, Regenerative medicine, Chronic pain, Combination, Collagen, Pelvis, CELU, Cytokine, Knee, Environment, Exosome, FDA, Disorder, Osteoarthritis, Device, Food, Decellularization, Dentistry, Protein, Disability, Chemokine, Sale, Tissue, GMP, Burns, Pharmaceutical industry

FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline. As used here, “net sales” refers exclusively to revenue from the sale of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as license fees and royalties or revenue earned under research collaboration agreements.

Key Points: 
  • FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.
  • “Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction.
  • The Company expects in future to update expected full year 2024 net sales of its advanced biomaterial product and biobanking businesses.
  • The Company’s advanced biomaterial product pipeline consists of four commercial-stage products and three development-stage product candidates.